KR-20260065691-A - METHOD FOR PROVIDING INFORMATION FOR DIAGNOSING THE SEVERITY OF MAJOR DEPRESSIVE DISORDER AND COMPOSITION FOR DIAGNOSIS

Abstract

The present invention relates to a method for providing information and a diagnostic composition for diagnosing the severity of major depressive disorder, and more specifically, to a method for providing information and a diagnostic composition for diagnosing the severity of major depressive disorder that can distinguish between severe major depressive disorder and non-severe major depressive disorder and monitor the course of treatment of major depressive disorder by including the step of measuring the ADCY9 gene expression level of a sample isolated from an individual.

Inventors

• 김형석
• 김소연
• 최윤주
• 이수현
• 김민하
• 전세민

Assignees

• 전남대학교산학협력단

Dates

Publication Date

20260511

Application Date

20241101

Claims (9)

1. A method for providing information for the diagnosis of the severity of major depressive disorder, comprising the step of measuring the ADCY9 gene expression level of a sample isolated from an individual.
2. A method for providing information for diagnosing the severity of major depressive disorder according to claim 1, wherein the sample is whole blood or peripheral blood.
3. A method for providing information for diagnosing the severity of major depressive disorder, wherein, in claim 1, the step of determining that the severity is more severe as the ADCY9 gene expression level is lower is further included.
4. A method for providing information for diagnosing the severity of major depressive disorder according to claim 1, further comprising the step of diagnosing major depressive disorder as severe if the expression level (2 -dCt ) of the ADCY9 gene is 0.2543 or less.
5. A method for providing information for diagnosing the severity of major depressive disorder according to claim 1, further comprising the step of confirming whether the severity of major depressive disorder improves based on trend data of the expression level of the ADCY9 gene.
6. A method for providing information for diagnosing the severity of major depressive disorder, wherein the method of claim 1 further comprises the step of checking the score of the Korean version of the depression screening tool (PHQ-9).
7. A composition for diagnosing the severity of major depressive disorder comprising a preparation capable of measuring the expression level of the ADCY9 gene.
8. A composition for diagnosing the severity of major depressive disorder according to claim 7, wherein the formulation is a primer, probe, DNA, RNA, PNA, antibody, peptide, aptamer, or compound.
9. A kit for diagnosing the severity of major depressive disorder comprising the diagnostic composition of claim 7 or 8.

Description

Method for providing information for diagnosing the severity of major depressive disorder and composition for diagnosis The present invention relates to a method for providing information for diagnosing the severity of major depressive disorder and a composition for diagnosing the severity of major depressive disorder. Major Depressive Disorder (MDD) is the most representative and severe form of depression, characterized by symptoms such as severe sadness, loss of interest, fatigue, and lethargy that persist almost every day for at least two weeks. It makes daily life difficult and can have a severe impact on social relationships. Major Depressive Disorder can be classified as a single episode (one occurrence of depression) or recurrent (multiple episodes of depression). According to the diagnostic criteria for Major Depressive Disorder, at least five symptoms must persist for at least two weeks. According to the World Health Organization (WHO), approximately 280 million people worldwide suffer from major depressive disorder, which accounts for about 5% of the total population and tends to occur more frequently in women. In Korea as well, major depressive disorder accounts for a significant portion of mental health issues. According to data from the National Health Insurance Service in 2021, 5–7% of domestic adults suffer from major depressive disorder, and this figure tends to increase with age. Major depressive disorder is classified into mild, moderate, and severe levels based on severity, and patients with severe cases fall into a depressed state so severe that daily life becomes nearly impossible. Severity is determined by the intensity of symptoms and the extent of functional impairment experienced by the patient; since severe cases increase the risk of suicide, prompt intervention and treatment are crucial. However, accurately assessing the severity of patients with major depressive disorder has traditionally been a significantly difficult task. It relies primarily on subjective reports based on the patient's mood and emotions; however, since the degree to which depression is expressed varies from person to person and patients often do not accurately describe their symptoms due to cultural background or personality, it makes objective assessment of severity difficult. Accordingly, the inventors of the present invention completed the present invention by researching an objective and highly accurate method for diagnosing the severity of major depressive disorder, selecting genes with different expression levels according to the severity of major depressive disorder, and confirming the effectiveness of differentiating the severity of major depressive disorder patients and monitoring the course of treatment. Figure 1 shows the results of a linear regression analysis showing the correlation between major depressive disorder and PHQ-9 scores. Figure 2 shows the results of the ROC curve analysis for the severe major depressive disorder patient group (PHQ-9 score of 20 or higher) and the non-severe major depressive disorder patient group (PHQ-9 score of less than 20). Figure 3 shows the measurement data for the ADCY9 gene expression level. Figure 4 shows the result of indicating the point with the highest Yuden index among the points on the ROC curve analyzing ADCY9 gene expression level measurement data. Figure 5 shows the calculated Spearman correlation coefficients between each item. Figure 6 shows the results of the weight analysis by gene using Logistric regression (LR). The present invention provides a method for providing information for diagnosing the severity of major depressive disorder and a diagnostic composition. The present invention provides a method for providing information for diagnosing the severity of major depressive disorder and a diagnostic composition, which can distinguish between severe major depressive disorder and non-severe major depressive disorder and monitor the course of treatment of major depressive disorder by including the step of measuring the ADCY9 gene expression level of a sample isolated from an individual. The severity of major depressive disorder can be assessed using the Korean version of the Patient Health Questionnaire-9 (PHQ-9) score. The PHQ-9 is a self-report questionnaire used to diagnose major depressive disorder and evaluate its severity. The PHQ-9 reflects the diagnostic criteria for depression based on the DSM-5 and consists of nine items designed to assess the frequency of depressive symptoms. Each item evaluates how often the patient experienced a specific symptom over the past two weeks using a scale from 0 to 3 points. The PHQ-9 consists of nine items, each scored from 0 to 3 points. Specifically, it consists of loss of interest or pleasure (feeling no interest or pleasure in almost any activity in the past 2 weeks), depression (feeling depressed or hopeless in the past 2 weeks), sleep problems (difficulty sleeping or excessive sleep), fatigue or leth